Trials / Completed
CompletedNCT03201718
A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs
Post-marketing Surveillance Study of Viekira/ Exviera Tablets for Korean Hepatitis C Patients According to the Standard for "Re-examination of New Drugs"
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 505 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Post-marketing surveillance study to evaluate the real world safety and effectiveness of Viekira/ Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by Korean patients with Hepatitis C.
Conditions
Timeline
- Start date
- 2017-08-17
- Primary completion
- 2019-10-11
- Completion
- 2019-10-11
- First posted
- 2017-06-28
- Last updated
- 2020-10-08
Locations
59 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03201718. Inclusion in this directory is not an endorsement.